A 2026 RMD Open narrative review of recombinant zoster vaccine (RZV) in inflammatory rheumatic disease — robust efficacy across IRD cohorts (~95% reduction in HZ recurrence; 54–70% effectiveness in SLE), no meaningful short-term flare signal in RCT data, and a practical drug-by-drug timing framework spanning csDMARDs, biologics, JAK inhibitors and B-cell depletion.
This 2026 Nature Reviews Rheumatology paper reframes SLE autoantibody production by contrasting the germinal-centre and extrafollicular B cell pathways — their distinct kinetics, affinity profiles, T cell dependence, and therapeutic vulnerabilities — showing that the inflammatory niche, not intrinsic autoreactivity, determines pathogenic B cell fate.
A contemporary NEJM review of idiopathic inflammatory myopathies — the five-subtype framework (IBM, IMNM, antisynthetase syndrome, overlap, dermatomyositis), the autoantibody revolution that now anchors classification, and the shift toward subtype-specific therapy with biologics, JAK/TYK2 inhibitors, and CAR-T.
CD19 CAR-T cellular therapy delivers drug-free remission in 80–85% of refractory SLE patients in early-phase trials, with similar signals in IIM and SSc — the first credible attempt at true immunological reset in autoimmune rheumatic disease.